OncoMatch/Clinical Trials/NCT06111625
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Is NCT06111625 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies blinatumomab for leukemia, lymphoid.
Treatment: blinatumomab — The goal of this single-arm, prospective study is to test in low-burden B-cell lymphoblastic leukemia (B-ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • The efficacy and safety of short-term blinatumomab as a bridging therapy to allo-HSCT in patients with low-burden B-ALL. Participants will take intravenous blinatumomab prior to allo-HSCT with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day and continued for 5 to 10 days. Dexamethasone 20mg was administered 1 hour before the onset of blinatumomab infusion.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Demographics
Prior therapy
Cannot have received: blinatumomab (blinatumomab)
Exception: administration for more than 14 days
administration of blinatumomab therapy for more than 14 days
Lab requirements
Kidney function
no renal dysfunction
Liver function
no decompensated liver dysfunction
Cardiac function
no myocardial infarction, no chronic heart failure
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06111625 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior blinatumomab disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 65 years or younger and at least 16 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify